Dissertation > Excellent graduate degree dissertation topics show

Correlation of Polymorphism C3435T of the MDR1 Gene and the Response of Epirubicine Containing Postoperative Adjuvant Chemotherapy in Women with Breast Cancer and Analysis of Prognosis

Author: YanPengWei
Tutor: HuangXinEn
School: Nanjing Medical University
Course: Oncology
Keywords: Multi-drug resistance epirubicine breast cancer adjuvant chemotherapy genetic polymorphisms
CLC: R737.9
Type: Master's thesis
Year: 2011
Downloads: 27
Quote: 0
Read: Download Dissertation

Abstract


Objective:To evaluate the relationship between polymorphism C3435T of the MDR1 gene and epirubicine containing regimens as postoperative adjuvant chemotherapy for breast cancer and detect prognositic factors.Methods:We observed the 5-year disease free survival (DFS) and adverse effect in breast cancer patients treated by epirubicine based postoperative chemotherapy from April 10th, 2003 to December 20th, 2005 and detected MDR1 gene codon 3435 genetic polymorphism by using real time polymerase chain reaction (RT-PCR). The relationship between genetic polymorphisms and survival after epirubicine based chemotherapy were analyzed by SPSS 13.0, and an analysis on possible prognostic factors was conducted.Results:(1) Genotype frequenciesAmong all 302 patients, the genotypes of MDR1 codon C3435T were C/C 122(40.4%), C/T 135(44.7%) and T/T 45(13.9%), respectively.(2) Genotype and survivalThe 5-year disease free survival (DFS) rate in all 302 patients was 85.1%. Patients with C/C genotype in MDR1 codon 3435 had a longer 5-year DFS (91.0%) than those with C/T (83.0%) and T/T (75.6%).151 patients were treated with 5-fluorouracil / epirubicine / cyclophosphamide (FEC) regimen, 49 patients with vinorelbine/ epirubicine (NE), 70 patients with paclitaxel/ epirubicine (TE) and 32 patients with paclitaxel/ epirubicine/ cyclophosphamide (TEC) regimen. 5-year DFS rates of patients treated by FEC, NE,TE and TEC regimens were 81.5%, 85.7%, 90.0% and 90.6%, respectively.(3) Chemotherapy related adverse effectAdverse effects of grade III or more include bone marrow suppression, gastrointestinal reaction and cardiac accident were respectively 37.1%, 25.2% and 0.6% in the cases with FEC regimen, 34.7%, 18.4% and 0.0% in the cases with NE regimen, 38.6%, 17.1% and 0.0% in the cases with TE regimen, and 37.5%, 18.8% and 3.1% in the cases with TEC regimen.(4) Prognostic factorsBy univariate analysis, there were statistically significant differences in the 5-year DFS rates between the patients with various T stage, lymph node metastasis, clinical stage, vascular invasion and genotypes in the MDR1 codon 3435. Multivariate Cox analysis showed clinical stage and MDR1 genotypes were the independent prognostic factors.Conclusion:FEC, NE, TE and TEC regimens with 4 to 6 courses could be proper postoperative chemotherapeutic regimens for breast cancer, and the chemotherapy related toxicity is acceptable. And these regimens could be recommended of adjuvant chemotherapy for patients with C/C genotype in MDR1 codon 3435, considering longer survival time was deteceted than patients with C/T and T/T genotype. The clinical stage and MDR1 genotypes were the independent prognostic factors for our cohort of patients.

Related Dissertations

  1. The Effects of Pu-erh Tea on Prevetion and Treatment of Tumor,R285.5
  2. The Related Study of Breast-conserving Surgery Plus Postoperative Tangential Irradiation,R737.9
  3. The Relevance Research between Breast Cancer Calcification X Performance and Pathology,R737.9
  4. Screen Genes Affected the Activity of Quorum Sensing Regulator VqmA and Functional Analysis of LysR and MFS Proteins in V.choleare,R378
  5. Comparative Analysis on CTF and CEF Regimens as Postoperative Adjuvant Chemotherapy in the Treatment of Phase Ⅱ Breast Cancer,R737.9
  6. The Correlation of Ultrasound Elasticity with the Expressions of Estrogen Receptor, Progestron Receptor, C-erbB-2 in Breast Cancer,R445.1
  7. Expressions of HOXA9 HOXA10 and HOXA11 in Breast Cancer,R737.9
  8. The Feasibility of the Immunohistochemistry Classification to Predicting Prognosis in Breast Cancer,R737.9
  9. The Experimental Study of Antiangiogenic and Induction of Apoptosis by Maximum Tolerated Dose Combined with Low-dose Cyclophosphamide in Breast Cancer,R737.9
  10. Maximum Tolerated Dose Combined with Metronomic Chemoterpy on Proliferation and Angiogenesis in Treatment of Breast Cancer,R737.9
  11. The Expression and Significance of Parathyroid Hormone-related Protein in Human Breast Cancer with Skeletal Metastases,R737.9
  12. The Shrink Pattern of Breast Cancer After Neoadjuvant Chemotherapy and the Correlation with Partial Clinic Pathological Factors: Preliminary Results of a Plot Study,R737.9
  13. Analysis of Clinial and Patholgoic Characteristics between the Han and the Uygur Patients with Triple-negative Breast Cancer,R737.9
  14. Clinical Signifinance of Combined Detection of Tumor Markers in Breast Cancer,R737.9
  15. The Relationship between CEF/TE Neo-adjuvant Chemotherapy, MAPK/PI3K Signal Pathway and Ki-67 in Breast Cancer,R737.9
  16. Effects of SILA409 on the Expression of GRP78 in Nci-h446 Human Small Cell Lung Cancer Cells and Its Correlation with Chemotherapy Resistance to VP-16,R734.2
  17. Isoflavone intake and the risk of breast and prostate cancer Meta-analysis,R737.25
  18. Mammographic X-ray analysis of false-negative breast cancer,R737.9
  19. Epidermal growth factor in breast carcinoma and its clinical significance 1,2,R737.9
  20. CK5 / 6 and EGFR as triple negative breast cancer prognostic factors analysis,R737.9
  21. Jieduhuayu party of the leukemia in K562/A02 HL60/ADR cell resistance reversal role,R733.7

CLC: > Medicine, health > Oncology > Genitourinary tumors > Breast tumor
© 2012 www.DissertationTopic.Net  Mobile